Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial.
Keil F, Müller AMS, Berghold A, Riedl R, Buxhofer-Ausch V, Schuster J, Vorburger C, Böhm A, Panny M, Nösslinger T, Greil R, Samaras P, Bencker C, Rütti M, Pabst T. Keil F, et al. Among authors: pabst t. EClinicalMedicine. 2023 Nov 19;66:102318. doi: 10.1016/j.eclinm.2023.102318. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38024477 Free PMC article.
Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma.
Messerli C, Wiedemann G, Porret N, Nagler M, Seipel K, Jeker B, Novak U, Zeerleder S, Bacher U, Pabst T. Messerli C, et al. Among authors: pabst t. Turk J Haematol. 2023 Aug 31;40(3):187-196. doi: 10.4274/tjh.galenos.2023.2023.0136. Epub 2023 Jul 31. Turk J Haematol. 2023. PMID: 37519105 Free PMC article.
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Pabst T, Papayannidis C, Demirkan F, Doronin V, Fogliatto LM, Guttke C, Gyan E, Hamad N, Herrera P, Hultberg A, Jacobs J, Johnson AJ, Langlois A, Ma X, Martinelli G, Arnan M, Müller R, Nottage K, Ofran Y, Özcan M, Samoilova O, Tolbert JA, Trudel GC, Xiu L, Vey N, Wei AH. Pabst T, et al. Lancet Haematol. 2023 Nov;10(11):e902-e912. doi: 10.1016/S2352-3026(23)00207-7. Lancet Haematol. 2023. PMID: 37914483 Clinical Trial.
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression.
Rieger MJ, Pabst T, Jeker B, Paul P, Bergamini F, Bühler MM, Condoluci A, Flammer AJ, Rossi D, Stussi G, Gerber B, Schwotzer R. Rieger MJ, et al. Among authors: pabst t. Ann Hematol. 2024 Oct;103(10):4163-4170. doi: 10.1007/s00277-024-05901-x. Epub 2024 Jul 17. Ann Hematol. 2024. PMID: 39020041 Free PMC article.
PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy.
Maru B, Messikommer A, Huang L, Seipel K, Kovecses O, Valk PJM, Theocharides APA, Mercier FE, Pabst T, McKeague M, Luedtke NW. Maru B, et al. Among authors: pabst t. Cell Rep Med. 2023 Sep 19;4(9):101191. doi: 10.1016/j.xcrm.2023.101191. Epub 2023 Sep 7. Cell Rep Med. 2023. PMID: 37683650 Free PMC article.
424 results